Colleen Redlinger

848 total citations
9 papers, 551 citations indexed

About

Colleen Redlinger is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Colleen Redlinger has authored 9 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Colleen Redlinger's work include Pancreatic and Hepatic Oncology Research (4 papers), Advanced Breast Cancer Therapies (2 papers) and HER2/EGFR in Cancer Research (2 papers). Colleen Redlinger is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Advanced Breast Cancer Therapies (2 papers) and HER2/EGFR in Cancer Research (2 papers). Colleen Redlinger collaborates with scholars based in United States. Colleen Redlinger's co-authors include Mark H. O’Hara, Peter J. O’Dwyer, Jina Ko, Stephanie S. Yee, David Issadore, Ben Z. Stanger, Neha Bhagwat, Taylor A. Black, Erica L. Carpenter and Ana De Jesus‐Acosta and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and Cancer Research.

In The Last Decade

Colleen Redlinger

9 papers receiving 545 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Colleen Redlinger United States	6	269	190	160	136	112	9	551
Nir Rozenblum Israel	8	100 0.4×	147 0.8×	75 0.5×	102 0.8×	70 0.6×	15	479
Chuanzhen Hu China	17	311 1.2×	114 0.6×	193 1.2×	111 0.8×	83 0.7×	36	694
Mau‐Shin Chi Taiwan	9	117 0.4×	62 0.3×	63 0.4×	81 0.6×	65 0.6×	17	327
Diego M. Avella United States	19	299 1.1×	462 2.4×	167 1.0×	79 0.6×	87 0.8×	38	1.0k
Brigitte A. van Oirschot Netherlands	13	281 1.0×	97 0.5×	54 0.3×	34 0.3×	30 0.3×	42	616
Peiyi Xie China	13	170 0.6×	260 1.4×	59 0.4×	84 0.6×	40 0.4×	45	616
Svetlana Gourevitch Israel	7	89 0.3×	121 0.6×	63 0.4×	72 0.5×	72 0.6×	9	391
Lie Yao China	15	177 0.7×	207 1.1×	100 0.6×	70 0.5×	39 0.3×	30	522
Claudia von Arx Italy	11	100 0.4×	219 1.2×	70 0.4×	37 0.3×	114 1.0×	31	461

Countries citing papers authored by Colleen Redlinger

Since Specialization

Citations

This map shows the geographic impact of Colleen Redlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colleen Redlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colleen Redlinger more than expected).

Fields of papers citing papers by Colleen Redlinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colleen Redlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colleen Redlinger. The network helps show where Colleen Redlinger may publish in the future.

Co-authorship network of co-authors of Colleen Redlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Colleen Redlinger. A scholar is included among the top collaborators of Colleen Redlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colleen Redlinger. Colleen Redlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Guerra, Carmen E., Sheila Kelly, Colleen Redlinger, Patricia Hernández, & Karen Glanz. (2021). Pancreatic Cancer Clinical Treatment Trials Accrual. American Journal of Clinical Oncology. 44(6). 227–231. 3 indexed citations

Clark, Amy S., Nicholas P. McAndrew, Andrea B. Troxel, et al.. (2019). Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. Clinical Cancer Research. 25(7). 2072–2079. 35 indexed citations

Karasic, Thomas B., Mark H. O’Hara, Arturo Loaiza‐Bonilla, et al.. (2019). Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer. JAMA Oncology. 5(7). 993–993. 220 indexed citations

Karasic, Thomas B., Mark H. O’Hara, Arturo Loaiza‐Bonilla, et al.. (2018). Abstract CT085: Randomized phase II trial of hydroxychloroquine in combination with gemcitabine/nab-paclitaxel to inhibit autophagy in pancreatic cancer: A SU2C-funded trial. Cancer Research. 78(13_Supplement). CT085–CT085. 1 indexed citations

Ko, Jina, Neha Bhagwat, Stephanie S. Yee, et al.. (2017). A magnetic micropore chip for rapid (<1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis. Lab on a Chip. 17(18). 3086–3096. 40 indexed citations

Ko, Jina, Neha Bhagwat, Stephanie S. Yee, et al.. (2017). Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes. ACS Nano. 11(11). 11182–11193. 207 indexed citations

Clark, Amy S., Peter J. O’Dwyer, Daniel F. Heitjan, et al.. (2014). A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 527–527. 16 indexed citations

Sohal, Davendra, James M. Metz, Weijing Sun, et al.. (2012). Toxicity study of gemcitabine, oxaliplatin, and bevacizumab followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy in patients with locally advanced pancreatic cancer.. Journal of Clinical Oncology. 30(4_suppl). 337–337. 2 indexed citations

Brose, Marcia S., Andrea B. Troxel, Maryann Redlinger, et al.. (2009). Effect of BRAF^V600E on response to sorafenib in advanced thyroid cancer patients. Journal of Clinical Oncology. 27(15_suppl). 6002–6002. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact